Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Rapamycin level
6 months
Yes
Mary Kay Koenig, MD
Principal Investigator
The University of Texas Health Science Center, Houston
United States: Institutional Review Board
HSC-MS-09-0259
NCT01031901
December 2009
June 2011
Name | Location |
---|---|
The University Of Texas Health Science Center | San Antonio, Texas 78229 |